Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nasopharyngeal Cancer – Pipeline Review, H1 2017, provides an overview of the Nasopharyngeal Cancer (Oncology) pipeline landscape.
Nasopharyngeal cancer is a rare type of head and neck cancer. It starts in the upper part of your throat, behind the nose. This area is called the nasopharynx. The risk factors of nasopharyngeal cancer may include Epstein-Barr virus. Symptoms of nasopharyngeal cancer may include blurry or double vision, difficulty speaking, including hoarseness, ear infections that keep coming back, face pain or numbness, headache, hearing loss, ringing in the ears. Treatment includes surgery, chemotherapy and radiation therapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Nasopharyngeal Cancer – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Nasopharyngeal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Nasopharyngeal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Nasopharyngeal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 9, 12, 9 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 7, 2 and 6 molecules, respectively.
Nasopharyngeal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Nasopharyngeal Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Nasopharyngeal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Nasopharyngeal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Nasopharyngeal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Nasopharyngeal Cancer (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Nasopharyngeal Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Nasopharyngeal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Advenchen Laboratories LLC
Ambrx Inc
arGEN-X BV
Ascentage Pharma Group Corp Ltd
Atara Biotherapeutics Inc
AVEO Pharmaceuticals Inc
BeiGene Ltd
Betta Pharmaceuticals Co Ltd
BioDiem Ltd
Biomics Biotechnologies Co Ltd
CBT Pharmaceuticals Inc
Celgene Corp
Cell Medica Ltd
F. Hoffmann-La Roche Ltd
GlaxoSmithKline Plc
MedImmune LLC
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
Neonc Technologies Inc
Novartis AG
Ono Pharmaceutical Co Ltd
Sapvax
Tessa Therapeutics Pte Ltd
Theravectys SA
Viracta Therapeutics Inc
Yabao Pharmaceutical Group Co Ltd
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Nasopharyngeal Cancer – Overview 7
Nasopharyngeal Cancer – Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Pipeline by Universities/Institutes 12
Products under Development by Companies 13
Products under Development by Universities/Institutes 15
Nasopharyngeal Cancer – Therapeutics Assessment 16
Assessment by Target 16
Assessment by Mechanism of Action 19
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Nasopharyngeal Cancer – Companies Involved in Therapeutics Development 26
Advenchen Laboratories LLC 26
Ambrx Inc 26
arGEN-X BV 27
Ascentage Pharma Group Corp Ltd 27
Atara Biotherapeutics Inc 28
AVEO Pharmaceuticals Inc 28
BeiGene Ltd 29
Betta Pharmaceuticals Co Ltd 29
BioDiem Ltd 30
Biomics Biotechnologies Co Ltd 30
CBT Pharmaceuticals Inc 31
Celgene Corp 31
Cell Medica Ltd 32
F. Hoffmann-La Roche Ltd 32
GlaxoSmithKline Plc 33
MedImmune LLC 33
Merck & Co Inc 34
Merck KGaA 34
Millennium Pharmaceuticals Inc 35
Neonc Technologies Inc 35
Novartis AG 36
Ono Pharmaceutical Co Ltd 36
Sapvax 37
Tessa Therapeutics Pte Ltd 37
Theravectys SA 38
Viracta Therapeutics Inc 38
Yabao Pharmaceutical Group Co Ltd 39
Nasopharyngeal Cancer – Drug Profiles 40
alisertib – Drug Profile 40
Antisense RNAi Oligonucleotide for Nasopharyngeal Cancer – Drug Profile 46
apatinib – Drug Profile 47
APG-1387 – Drug Profile 51
ARGX-110 – Drug Profile 52
ATA-129 – Drug Profile 57
atezolizumab – Drug Profile 60
avelumab – Drug Profile 77
azacitidine – Drug Profile 86
baltaleucel-T – Drug Profile 92
bevacizumab – Drug Profile 94
BGBA-317 – Drug Profile 106
CBT-501 – Drug Profile 108
Cellular Immunotherapy for EBV Associated Malignancies – Drug Profile 109
Cellular Immunotherapy for Multiple Sclerosis and Nasopharyngeal Cancer – Drug Profile 110
Cellular Immunotherapy for Multiple Sclerosis and Nasopharyngeal Carcinoma – Drug Profile 111
Cellular Immunotherapy for Nasopharyngeal Cancer – Drug Profile 112
Cellular Immunotherapy for Oncology – Drug Profile 113
Cellular Immunotherapy for Oncology – Drug Profile 114
Cellular Immunotherapy for Oncology – Drug Profile 116
Cellular Immunotherapy to Target EPCAM for Oncology – Drug Profile 117
Cellular Immunotherapy to Target Latent Membrane Protein-2 for Oncology – Drug Profile 118
Cellular Immunotherapy to Target LMP1 for Epstein-Barr Virus Infections and Nasopharyngeal Cancer – Drug Profile 119
DC-120 – Drug Profile 120
donafenib – Drug Profile 121
durvalumab + tremelimumab – Drug Profile 122
EBViNT – Drug Profile 127
Epstein-Barr virus vaccine – Drug Profile 128
ficlatuzumab – Drug Profile 129
GSK-2849330 – Drug Profile 132
icotinib hydrochloride – Drug Profile 133
JS-001 – Drug Profile 135
MAK-683 – Drug Profile 136
Monoclonal Antibodies to Inhibit GAL-9 for Nasopharyngeal Carcinoma – Drug Profile 137
Monoclonal Antibody Drug Conjugate to Target CD70 for Nasopharyngeal Cancer and Renal Cell Carcinoma – Drug Profile 138
MVA vaccine – Drug Profile 139
NEO-212 – Drug Profile 140
nimotuzumab – Drug Profile 141
nivolumab – Drug Profile 145
PDR-001 – Drug Profile 185
pembrolizumab – Drug Profile 187
RO-5203280 – Drug Profile 235
Small Molecule to Antagonize DDR1 Receptor for NSCLC and Nasopharyngeal Cancer – Drug Profile 236
SV-638 – Drug Profile 237
TT-10 – Drug Profile 238
Vaccine for Nasopharyngeal Cancer and Hodgkin Lymphoma – Drug Profile 239
Vaccine for Oncology – Drug Profile 240
Vaccine to Target EBV for Nasopharyngeal Carcinoma – Drug Profile 241
Vaccine to Target LMP-2 for Nasopharyngeal Carcinoma – Drug Profile 242
VRx-3996 – Drug Profile 243
Nasopharyngeal Cancer – Dormant Projects 245
Nasopharyngeal Cancer – Discontinued Products 246
Nasopharyngeal Cancer – Product Development Milestones 247
Featured News & Press Releases 247
Appendix 253
Methodology 253
Coverage 253
Secondary Research 253
Primary Research 253
Expert Panel Validation 253
Contact Us 253
Disclaimer 254
List of Tables
Number of Products under Development for Nasopharyngeal Cancer, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Nasopharyngeal Cancer – Pipeline by Advenchen Laboratories LLC, H1 2017
Nasopharyngeal Cancer – Pipeline by Ambrx Inc, H1 2017
Nasopharyngeal Cancer – Pipeline by arGEN-X BV, H1 2017
Nasopharyngeal Cancer – Pipeline by Ascentage Pharma Group Corp Ltd, H1 2017
Nasopharyngeal Cancer – Pipeline by Atara Biotherapeutics Inc, H1 2017
Nasopharyngeal Cancer – Pipeline by AVEO Pharmaceuticals Inc, H1 2017
Nasopharyngeal Cancer – Pipeline by BeiGene Ltd, H1 2017
Nasopharyngeal Cancer – Pipeline by Betta Pharmaceuticals Co Ltd, H1 2017
Nasopharyngeal Cancer – Pipeline by BioDiem Ltd, H1 2017
Nasopharyngeal Cancer – Pipeline by Biomics Biotechnologies Co Ltd, H1 2017
Nasopharyngeal Cancer – Pipeline by CBT Pharmaceuticals Inc, H1 2017
Nasopharyngeal Cancer – Pipeline by Celgene Corp, H1 2017
Nasopharyngeal Cancer – Pipeline by Cell Medica Ltd, H1 2017
Nasopharyngeal Cancer – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Nasopharyngeal Cancer – Pipeline by GlaxoSmithKline Plc, H1 2017
Nasopharyngeal Cancer – Pipeline by MedImmune LLC, H1 2017
Nasopharyngeal Cancer – Pipeline by Merck & Co Inc, H1 2017
Nasopharyngeal Cancer – Pipeline by Merck KGaA, H1 2017
Nasopharyngeal Cancer – Pipeline by Millennium Pharmaceuticals Inc, H1 2017
Nasopharyngeal Cancer – Pipeline by Neonc Technologies Inc, H1 2017
Nasopharyngeal Cancer – Pipeline by Novartis AG, H1 2017
Nasopharyngeal Cancer – Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
Nasopharyngeal Cancer – Pipeline by Sapvax, H1 2017
Nasopharyngeal Cancer – Pipeline by Tessa Therapeutics Pte Ltd, H1 2017
Nasopharyngeal Cancer – Pipeline by Theravectys SA, H1 2017
Nasopharyngeal Cancer – Pipeline by Viracta Therapeutics Inc, H1 2017
Nasopharyngeal Cancer – Pipeline by Yabao Pharmaceutical Group Co Ltd, H1 2017
Nasopharyngeal Cancer – Dormant Projects, H1 2017
Nasopharyngeal Cancer – Discontinued Products, H1 2017
List of Figures
Number of Products under Development for Nasopharyngeal Cancer, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
